GLP-1
The battle of the bulge is ongoing and it appears that Americans are losing, according to a report from the U.S. Centers for Disease Control and Prevention. The report shows that Americans are losing height and gaining girth.
Galapagos NV will participate in the 37th Annual J.P. Morgan Healthcare Conference on January 8 & 9, 2019.
Fidelta Ltd is pleased to announce that it has signed an integrated drug discovery agreement with Galapagos based on Fidelta’s macrocyclic platform.
Galapagos NV announced today that the FDA has granted GLPG1972/S201086 Fast Track designation for the treatment of patients with osteoarthritis (OA).
Galapagos NV announces a share capital increase arising from warrant exercises.
Results to be presented at the AASLD congress 2018, 9-13 November
Galapagos NV reports first dosing in the PINTA Phase 2 trial with its GPR84 antagonist GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF).
PARAS BIOPHARMACEUTICALS FINLAND OY is currently enhancing its GMP, quality systems and production facilities for biopharmaceuticals – also known as biologics – with significant investments in new infrastructure and equipment.
Indianapolis-based Eli Lilly announced that its diabetes drug Trulicity (dulaglutide) reduced major adverse cardiovascular events (MACE) in its REWIND clinical trial.
Galapagos NV announces its unaudited Q3 results, which are further detailed in its Q3 2018 report available on the Galapagos website, www.glpg.com.
PRESS RELEASES